Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions
A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Shubin Qiao, MD
- Phone Number: +86 13701237893
- Email: qli@ccrfmed.com;qsbfw@sina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Recruiting
- Fuwai Hospital,National Center for Cardiovasular disease
-
Contact:
- Shubin Qiao, MD
- Phone Number: +86 13701237893
- Email: qsbfw@sina.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 years and ≤ 75 years, male or female without pregnancy;
- Patients with clinical evidence of asymptomatic heart disease, stable or unstable angina, or old myocardial infarction;
- De novo lesions of native coronary arteries;
- Target vessel diameter between 2.25mm and 4.5 mm, and target lesion length ≤ 60mm by visual estimation;
- Target lesion diameter stenosis ≥ 70% by visual estimation;
- Each target lesion must be implanted the same stent (CRE8);
- Patients is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG);
- Patients with left ventricular ejection fraction ≥40%;
- Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consents.
Exclusion Criteria:
- Patients with acute myocardial infarction (AMI) within 72 hours;
- Chronic total occlusion lesion (TIMI flow 0 before procedure), Left main disease and/or triple-vessel lesion that might require treatment;
- Heavily calcified or tortuous lesions which cannot be successfully pre-dilated, and lesions which are not suitable for stent delivery and deployment;
- In-stent restenosis;
- Thrombotic lesions;
- Patients who had received any other stent in the past one year;
- Patients with acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl);
- Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or with a history of active gastrointestinal bleeding, ulcer, cerebral hemorrhage or subarachnoid hemorrhage and stroke within 6 months;
- Patients who allergic to aspirin, clopidogrel, ticagrelor, ticlopidine, heparin, contrast agent, sirolimus, polymer, Co-Cr alloy, or with contraindication to aspirin or clopidogrel or ticagrelor;
- Patients with life expectancy less than 1year;
- Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint;
- Patient is in the opinion of the investigator, unable to comply with the requirements of the study protocol;
- Patients who had underwent heart transplant surgery.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
CRE8 group
CRE8 sirolimus-eluting stent
|
The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter.
This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Target lesion failure (TLF,device-oriented endpoint)
Time Frame: 12months after the procedure
|
12months after the procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Target lesion failure (TLF,device-oriented endpoint)
Time Frame: 1month,6months,2years,3years,4years and 5years follow-up
|
1month,6months,2years,3years,4years and 5years follow-up
|
|
The patient-oriented composite endpoint includes all-cause death, all MIs, or any revascularizations
Time Frame: 1month,6months,12months and annually up to 5years follow-up
|
1month,6months,12months and annually up to 5years follow-up
|
|
Stent thrombosis per ARC definition
Time Frame: 1month,6months,12months and annually up to 5years follow-up
|
1month,6months,12months and annually up to 5years follow-up
|
|
device and lesion success rates
Time Frame: immidiately after the procedure
|
immidiately after the procedure
|
|
clinical success rate
Time Frame: 7 days after the procedure
|
7 days after the procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shubin Qiao, MD, Fu Wai Hospital, National Center for Cardiovasular disease
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
Other Study ID Numbers
- CRE8-China-SA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.